BTIG Maintains Buy on Insulet, Lowers Price Target to $235

Benzinga Newsdesk www.benzinga.com Negative 85.9%

Neg 85.9% Neu 0% Pos 0%

BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $260 to $235.

Comments

No comments yet. Be the first!